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Bleeding and Thrombosis
Risk Matters
How Long Can We Stick to the One-Size-Fits-All
Strategy of Platelet Inhibition?*
Dirk Sibbing, MD, Lisa Gross, MD,
Martin Orban, MD, Steffen Massberg, MD
Munich, Germany
During the last decades, a dual antiplatelet treatment with
aspirin and a P2Y12 platelet receptor inhibitor has become the
cornerstone of medical therapy for patients with coronary
artery disease presenting with acute coronary syndromes
(ACS) or undergoing a percutaneous coronary intervention
(PCI). Whereas drug response variability to antiplatelet
agents and especially to P2Y12 receptor inhibitors such as
clopidogrel (1) or prasugrel (2) is a widely accepted and
thoroughly investigated phenomenon, and whereas it is
obvious that both bleeding and thrombotic events have an
impact on overall survival of PCI-treated patients (3),
a personalized and thereby tailored treatment with regard to
drug choice and dosage adjustment is still not reality in clinical
practice. Studies (1,4) performed a decade ago have stimu-
lated extensive research in this ﬁeld, and the idea of a thera-See page 854peutic window of platelet inhibition that reﬂects both
bleeding and thrombotic risk was postulated (5) early after the
ﬁrst reports on clopidogrel response variability. Initial
evidence for the existence of a “sweet-spot” of P2Y12 receptor-
directed inhibition was provided by an observational study
performed in clopidogrel-treated patients (n ¼ 2,533)
undergoing PCI (6). Subsequent studies (7–10) focusing on
the therapeutic window concept and using different platelet
function assays for drug response monitoring have conﬁrmed
these ﬁndings (for a summary of studies see Table 1).
In this issue of JACC: Cardiovascular Interventions,
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reactivity (VLTPR) as well as on the therapeutic window of
platelet inhibition in ACS patients (n ¼ 1,542) receiving
clopidogrel or prasugrel for PCI. Using the laboratory-based
P2Y12 receptor-speciﬁc vasodilator-stimulated phospho-
protein assay for platelet function monitoring, the investi-
gators observed that VLTPR was found to be a strong and
independent predictor of bleeding complications. The
prognostic value of VLTPR was consistent across different
types of thienopyridines used in this study. Patients within
a window of normal platelet reactivity showed the lowest risk
(5.7%) for adverse events (deﬁned as the combined incidence
of stent thrombosis or bleeding events grade 2 deﬁned
according to Bleeding Academic Research Consortium
criteria) when compared with a 17.4% event rate in VLTPR
patients and 8% events in patients with high on-treatment
platelet reactivity (padj ¼ 0.02). Interestingly, the presence of
diabetes and a PCI for ST-segment elevation myocardial
infarction were both associated with a lower bleeding risk in
different subgroups of the study; a ﬁnding that is in line with
results from the TRITON-TIMI 38 (Trial to Assess Im-
provement in Therapeutic Outcomes by Optimizing Platelet
Inhibition With Prasugrel–Thrombolysis In Myocardial
Infarction) trial (12), where exactly these subgroups derived
the greatest beneﬁt from prasugrel treatment and this
without a higher risk for bleeding. With the present results,
the investigators conﬁrm and expand prior reports (13) on
the association of an enhanced response to P2Y12 receptor
inhibitors with bleeding risk. Furthermore, this study calls
for greater attention to the therapeutic window concept of
platelet inhibition. Some aspects of their study require
a closer look and a critical discussion.
First, the investigators assessed the response to thienopyr-
idine treatment at 1 month after the PCI procedure. The
optimal time point of testing, however, may depend on the
clinical scenario and the P2Y12 receptor inhibitor that was
chosen for the initial treatment. Considering that in general,
but especially in clopidogrel low responders, the majority of
thrombotic events occur in the early phase after the inter-
vention (12), any testing that aims at intensifying treatment
(e.g., switch from clopidogrel to prasugrel) should be made
early after the PCI procedure. Then again, it may well be that
platelet function monitoring beyond the acute phase and
in the subacute phase of treatment may prove useful for
reducing bleeding risk by establishing a more differentiated
treatment regimen that is characterized by high-level platelet
inhibition in the acute phase and a more moderate level
(deintensiﬁcation) of inhibition in the subacute and chronic
phase of treatment (e.g., switch from prasugrel back to
clopidogrel). Second, the present study (11) is of observational
nature, and the results reported call for randomized studies
using the vasodilator-stimulated phosphoprotein technique
or other near-patient testing methods in ACS patients
undergoing PCI.
Table 1. Studies on the Therapeutic Window Concept of Platelet Inhibition in Patients Treated With PCI
First Author (Ref. #) Patients, n Platelet Function Assay Study Cohort Drug Investigated Therapeutic Window Range
Bonello et al. (8) 301 VASP assay ACS patients Prasugrel PRI VASP: 16%–53.5%
Campo et al. (7) 300 Verify Now P2Y12 assay All comers (except STEMI patients) Clopidogrel PRU: 86–238
Cuisset et al. (11) 1,542 VASP assay ACS patients Clopidogrel and prasugrel PRI VASP: 10%–50%
Gurbel et al. (10) 225 TEG platelet mapping assay ACS patients Clopidogrel MA ADP: 31–47 mm
Mangiacapra et al. (9) 732 Verify Now P2Y12 assay Stable CAD patients Clopidogrel PRU: 179–238
Sibbing et al. (6) 2,533 Multiplate analyzer All comers Clopidogrel AU  min: 189–467
ACS ¼ acute coronary syndromes; ADP ¼ adenosine diphosphate; AU = aggregation units; CAD ¼ coronary artery disease; MA ¼ maximal aggregation; PCI ¼ percutaneous coronary intervention; PRI ¼
platelet reactivity index; PRU ¼ P2Y12 reactivity units; TEG ¼ thromboelastogram; VASP ¼ vasodilator-stimulated phosphoprotein.
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865Whereas the value of platelet function testing as a diag-
nostic or prognostic tool in PCI-treated patients is beyond
any doubt (4), the assets and drawbacks of a personalized
antiplatelet treatment based on platelet function monitoring
are subject to controversial discussions. Prior randomized
trials (14–16) that implemented the VerifyNow P2Y12 assay
did not support a personalized approach of antiplatelet
treatment. However, these studies had little or no utilization
of potent P2Y12 receptor inhibitors such as prasugrel or
ticagrelor (14,15) or included mainly patients with stable
coronary artery disease (14–16)da group of patients where
overall event rates are low and leave little room for
improvement. Similar as the case in the present study by
Cuisset et al. (11) was, future trials on personalized anti-
platelet treatment should focus on high-risk cohorts such as
ACS patients undergoing PCI and should also focus on
stent thrombosis and bleeding events with regard to the
primary endpoint selection.
Concerning the optimal level of platelet inhibition in
the individual patient, both mechanistic and clinical data
(4,12) are not in accordance with a “1-size-ﬁts-all” strategy
of antiplatelet treatment. We have learned from the pivotal
randomized trials (12,17) in this ﬁeld, that the risk for
bleeding and thrombotic events is also a group-speciﬁc
property. Whereas, for example, diabetic or ST-segment
elevation myocardial infarction patients are likely to require
the adequate action of potent antiplatelet agents, the same
treatment may lead to an unfavorable risk-beneﬁt proﬁle in
other groups such as elderly patients or patients with a low
body mass index.
Nowadays, it is common practice in coronary artery
disease patients to adjust the dosing of lipid-lowering agents
based on measured low-density lipoprotein levels and to
adjust the antihypertensive medication based on measured
blood pressure values. However, for antiplatelet drugs, where
an adequate response is crucial for clinical outcome, an
individualized treatment approach reﬂecting both bleeding
and thrombotic risk has not yet been established. The
question remains how long we can carry on regardless with
this 1-size-ﬁts-all approach of targeting the blood platelet.Reprint requests and correspondence: Dr. Dirk Sibbing, I.
Medizinische Klinik und Poliklinik, Ludwig-Maximilians-Uni-
versität München, Marchioninistr. 15, 81377 München, Germany.
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